In this study, using 4-ipp in combination with ipilimumab, the authors conclude that improved anti-CTLA-4 anti-tumour effect is a result of reprogramming the metabolism of metastatic melanoma by reducing hypoxia, thus improving immunogenicity and anti-tumour efficacy [120] (Fig. 3c). The gene discussed is CTLA4; the disease is neoplasm.